Tirofiban and emergency coronary surgery.

@article{Shanmugam2005TirofibanAE,
  title={Tirofiban and emergency coronary surgery.},
  author={Ganesh N Shanmugam},
  journal={European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery},
  year={2005},
  volume={28 4},
  pages={
          546-50
        }
}
The final common pathway of platelet aggregation leading to coronary thrombosis involves cross-linking of platelet receptor glycoprotein IIb-IIIa by primarily fibrinogen. Glycoprotein IIb-IIIa antagonists are being increasingly used as adjunctive therapy during percutaneous coronary intevention, and have shown to reduce the risk of death and myocardial infarction. However, a proportion of these patients continue to remain ischemic and present for emergency coronary grafting. The profound… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Clinical experience in coronary bypass surgery for abciximab-treated patients.

  • The Annals of thoracic surgery
  • 2000
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

PRISM-PLUS Study Investigators
  • Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms
  • 1998
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

PRISM-PLUS Study Investigators
  • Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms
  • 1998
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers